S.R. Drugs And Intermediates (Unit 3) Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 4 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth %
- Ebitda
- Net Worth
- Total Assets -3.85%
About S.R. Drugs And Intermediates (Unit 3)
S.R. Drugs And Intermediates (Unit 3) Private Limited (SDAIU3PL) is a Private Limited Indian Non-Government Company incorporated in India on 03 June 2020 (Four years and seven months 30 days old ). Its registered office is in Medak, Telangana, India.
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Satyanarayana Chinnamail and Satyanarayana Khairtabad serve as directors at the Company.
Company Details
-
Location
Medak, Telangana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24230TG2020PTC140573
-
Company No.
140573
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
03 Jun 2020
-
Date of AGM
20 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at S.R. Drugs And Intermediates (Unit 3)?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Satyanarayana Chinnamail
|
Director | 03-Jun-2020 | Current |
|
Satyanarayana Khairtabad
|
Director | 03-Jun-2020 | Current |
Financial Performance of S.R. Drugs And Intermediates (Unit 3).
S.R. Drugs And Intermediates (Unit 3) Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of S.R. Drugs And Intermediates (Unit 3)?
Unlock access to S.R. Drugs And Intermediates (Unit 3)'s control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
S.R. Drugs And Intermediates Pvt.Ltd.Satyanarayana Chinnamail and Satyanarayana Khairtabad are mutual person
-
Arene Life Sciences (Unit 3) Private Limited
Satyanarayana Chinnamail and Satyanarayana Khairtabad are mutual person
-
-
Arene Life Sciences Private LimitedSatyanarayana Chinnamail and Satyanarayana Khairtabad are mutual person
-
Arene Life Sciences (Unit 4) Private Limited
Satyanarayana Chinnamail and Satyanarayana Khairtabad are mutual person
-
Srduo Infra LlpSatyanarayana Chinnamail and Satyanarayana Khairtabad are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at S.R. Drugs And Intermediates (Unit 3)?
S.R. Drugs And Intermediates (Unit 3) has a workforce of 0 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of S.R. Drugs And Intermediates (Unit 3), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped S.R. Drugs And Intermediates (Unit 3)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.